Kura Oncology
Yahoo Finance • 7 months ago
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Kura Oncology, Inc. SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today an... Full story
Yahoo Finance • 10 months ago
Kura Makes Good On Its $150 Million Infusion And Shoots Up 12%
Kura stock surged to a nearly three-year high Tuesday after Kura Oncology unveiled promising test results for its leukemia treatment. Continue reading... Full story
Yahoo Finance • 12 months ago
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy... Full story
Yahoo Finance • last year
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2023 Kura Oncology Inc. Earnings Conference Call. At this time, all lines... Full story
Yahoo Finance • last year
Kura Oncology Reports Third Quarter 2023 Financial Results
– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of ziftomenib anticipated early in first quarte... Full story
Yahoo Finance • last year
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, I... Full story
Yahoo Finance • last year
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy... Full story
Yahoo Finance • last year
Kura Oncology to Report Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it wi... Full story
Yahoo Finance • last year
Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806
– Phase 1 dose-escalation study to evaluate KO-2806 as a monotherapy and in combination with targeted therapies in KRASG12C-mutant NSCLC and ccRCC – SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clin... Full story
Yahoo Finance • last year
Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC
– Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR – – Data validate activity of farnesyltransferase inhibitors and support rapid advancement of KO-2806 into combinations with targeted therapi... Full story
Yahoo Finance • last year
14 Best Cancer Stocks To Buy Now
In this article, we discuss 14 best cancer stocks to buy. If you want to skip our detailed discussion on the oncology industry, head directly to 5 Best Cancer Stocks To Buy Now. The global oncology landscape continues to evolve, with ongo... Full story
Yahoo Finance • last year
Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12D inhibitors – SAN DIEGO, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nas... Full story
Yahoo Finance • last year
Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer
– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors – – Company to include KRASG12C-mutant NSCLC in combination portion of Phase 1 clinical trial of KO-2806 (FIT-001) – SA... Full story
Yahoo Finance • last year
Kura Oncology to Participate in Cantor Global Healthcare Conference 2023
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its parti... Full story
Yahoo Finance • last year
Kura Oncology Appoints Brian Powl as Chief Commercial Officer
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appoi... Full story
Yahoo Finance • last year
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricin... Full story
Yahoo Finance • last year
Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it ha... Full story
Yahoo Finance • last year
Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib – – Z... Full story
Yahoo Finance • 2 years ago
Kura Oncology Reports First Quarter 2023 Financial Results
– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML outperforming projections – – First com... Full story
Yahoo Finance • 2 years ago
Kura Oncology to Participate in JMP Securities Life Sciences Conference
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its partici... Full story
